StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.41−0.22 (-0.83%)

Close on Nov 17, 2026Market cap $1.70BP/E –Yield –

Stoke Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Stoke Therapeutics's price to sales ratio was 62.8× on Nov 11, 2026, against 8.3× a year earlier. Over the last 4 years it ranged from 2.7× to 88.7×, with a median of 28.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202662.8×+54.3
2025Dec 31, 20258.5×−26.4
2024Dec 31, 202434.9×+9.7
2023Dec 29, 202325.2×–

More Stoke Therapeutics figures

See a number that looks wrong?